This article analyzes the considerations regarding the optimal design of a pivotal Phase III biosimilar study.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
Subgroups, Study Design, and the Impact of the Biosimilar Extension Rule
How and when to accommodate a subgroup in your biosimilar study
Read more
